Metastatic cancer is not always stage 4, even though the two terms are treated as interchangeable in everyday conversation and even in many clinical settings. For the majority of solid tumors staged under the widely used TNM system, distant metastasis does automatically place a cancer in stage IV. But several important categories break that rule: some cancers use entirely different staging frameworks, certain tumor types can carry a stage IV label without any distant spread, and a few rare pediatric cancers can be metastatic yet carry a stage designation that is explicitly not stage 4. Understanding why the shorthand “metastatic equals stage 4” falls apart in specific situations matters for treatment decisions, prognosis, and how patients interpret their own diagnosis.
Where the “Metastatic Equals Stage 4” Rule Comes From
Most solid tumors in adults are staged using the TNM system, which the American Joint Committee on Cancer (AJCC) maintains and periodically updates. The T describes the size and local extent of the primary tumor, the N describes regional lymph node involvement, and the M describes whether the cancer has spread to distant organs. When M is positive for distant spread, the overall stage grouping is almost always IV. This is the origin of the widespread assumption: in the TNM framework for common cancers like lung, colon, and breast, a positive M is essentially the defining feature of stage IV.
That assumption holds remarkably well across most solid tumors. If someone is told they have stage IV colon cancer, it means the cancer has reached a distant site like the liver or lungs. The same applies to melanoma, pancreatic cancer, and most other tumors staged by the AJCC. But the TNM system is not the only staging system in oncology, and even within TNM-staged cancers, the relationship between metastasis and stage IV is not perfectly one-to-one.
Stage IV Without Distant Metastasis
One of the more counterintuitive exceptions is that some cancers can be classified as stage IV even when no distant organ has been reached. Prostate cancer provides a clear example. Under current staging conventions, a prostate tumor that has spread extensively into regional pelvic lymph nodes but has not traveled to distant organs can be classified as stage IVA. A case report described a patient with a bulky locally advanced prostate tumor and extensive regional lymph node involvement but no distant metastasis who was classified as having stage IVA (T3bN1M0) disease.1PubMed Central. Advanced prostate cancer presenting as bulky loco-regional disease without distant metastasis: a case report with review of the management – What is the optimal treatment? The M0 in that designation literally means no distant metastasis, yet the overall stage is IV.
This happens because in certain cancers, the staging system recognizes that regional spread can be so extensive that outcomes and treatment approaches align more closely with what we think of as advanced disease, even without a distant metastatic deposit. It is a reminder that stage groupings are ultimately about prognosis and guiding therapy, not about whether the word “metastasis” technically applies.
Cancers That Do Not Use the TNM System at All
The TNM system dominates staging for most solid tumors, but it is not universal. Blood cancers and brain tumors each have their own staging or grading frameworks, and the concept of “stage 4” works differently or does not exist in the same form.
Lymphomas and Blood Cancers
Non-Hodgkin lymphoma, for instance, is staged using the Ann Arbor system rather than TNM.2PubMed. Staging non-Hodgkin lymphoma The Ann Arbor system does go from stage I to stage IV, but it describes the pattern and extent of lymph node and organ involvement rather than primary tumor characteristics and distant spread in the way TNM does. A lymphoma patient with stage IV disease has involvement of organs beyond the lymphatic system, like bone marrow, but the biology and treatment of that scenario are fundamentally different from, say, stage IV lung cancer with liver metastases. Leukemias, meanwhile, are staged using still other systems that may not include numerical stages at all. A patient with chronic lymphocytic leukemia might be staged using the Rai or Binet systems, which use categories that bear no resemblance to the I-through-IV framework of solid tumors.
Brain Tumors
Primary brain tumors are another major exception. The World Health Organization grades central nervous system tumors on a scale that reflects how aggressive the tumor cells look under a microscope and what molecular markers they carry, rather than how far the cancer has spread. The 2021 WHO classification grades IDH-mutant astrocytomas as grade 2, 3, or 4, with glioblastomas designated as IDH-wildtype.3PubMed Central. Early High-Grade Transformation of IDH-Mutant Central Nervous System WHO Grade 2 Astrocytoma: A Case Report A WHO grade 4 brain tumor is the most aggressive category, but that “4” refers to the histological and molecular behavior of the tumor cells, not to the presence of distant metastases. In fact, primary brain tumors rarely metastasize outside the central nervous system. A grade 4 glioblastoma is extremely serious, but calling it “stage 4” in the way that applies to metastatic colon or breast cancer would be misleading.
Metastatic but Explicitly Not Stage 4
Perhaps the most striking exception to the “metastatic equals stage 4” rule comes from pediatric oncology. Neuroblastoma, a cancer that primarily affects infants and young children, has a staging category called 4S (sometimes written as “stage 4S” or “MS” in newer nomenclature). A child with 4S neuroblastoma has cancer that has spread from its primary site to the liver, skin, or bone marrow. That is, by any reasonable definition, metastatic disease. Yet 4S is deliberately classified as a separate category from stage 4 because these children have dramatically better outcomes.
Neuroblastoma is unique among human cancers in its tendency to undergo spontaneous regression, and this is most evident in infants with stage 4S disease.4PubMed Central. Spontaneous regression of neuroblastoma Patients younger than 12 months with the 4S pattern of metastases (limited to liver, skin, and bone marrow) have substantially better outcomes than infants with true stage 4 disease, and the International Neuroblastoma Risk Group staging system now extends the age cutoff for this favorable category to 18 months.5PubMed Central. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age Some of these tumors literally shrink and disappear on their own. Lumping 4S into “stage 4” would wildly overstate the threat and could lead to unnecessary aggressive treatment in babies who may not need it.
Cancer of Unknown Primary
Another scenario that disrupts the equation is cancer of unknown primary, or CUP. This is a diagnosis given when metastatic cancer is found in the body but the original tumor it came from cannot be identified despite thorough investigation. CUP accounts for a meaningful fraction of cancer diagnoses and is characterized by early metastatic spread in atypical patterns, an aggressive clinical course, and poor response to standard chemotherapy.6PubMed Central. Metastatic Cancer of Unknown Primary or Primary Metastatic Cancer?
Because the standard staging systems are built around the characteristics of a known primary tumor, CUP patients often cannot be formally staged in the usual sense. You cannot assign a T category when you do not know where the primary tumor is, or even what organ it arose in. These patients unquestionably have metastatic disease, but applying a “stage IV” label requires a staging system, and the relevant staging system requires knowing the cancer type. In practice, CUP is treated as advanced metastatic cancer, but the staging terminology itself does not apply cleanly.
Oligometastatic Disease and the Gray Zone
Even within cancers that do use the TNM system and do carry a stage IV label when metastatic, not all metastatic disease behaves the same. The concept of oligometastatic disease describes a state that exists in a transitional zone between truly localized cancer and widespread systemic disease.7PubMed Central. The biology and treatment of oligometastatic cancer A patient with a single small metastasis in the liver from an otherwise controlled colon cancer is technically stage IV, but their situation is biologically and clinically different from someone with widespread metastatic deposits throughout multiple organs.
This matters because patients with oligometastatic disease may be candidates for treatments aimed at long-term control or even cure, including surgery to remove the isolated metastasis or focused radiation. The stage IV label alone does not capture this nuance. Two patients can both be “stage IV” yet face strikingly different prognoses and treatment options depending on the number, location, and biology of their metastases. The staging system was originally designed to sort patients into broad prognostic groups, and oligometastatic disease is an area where the broad grouping is too crude to reflect real clinical differences.
Why Staging Is Becoming More Than Anatomy
The traditional staging approach focused almost entirely on anatomy: how big is the tumor, how many lymph nodes are involved, and has it spread to distant sites. But the eighth edition of the AJCC Cancer Staging Manual, the current version, has moved toward incorporating molecular and biological markers into staging alongside anatomic extent.8PubMed. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging
Breast cancer staging is the most prominent example. Biological markers like estrogen receptor status, progesterone receptor status, HER2 status, and tumor grade now factor directly into the stage grouping. This means two breast cancers with identical tumor sizes, lymph node involvement, and metastatic status can receive different stage assignments based on their molecular profiles.9PubMed Central. American Joint Committee on Cancer’s Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians These advances reflect the recognition that anatomy alone does not explain why patients with seemingly similar cancers have very different outcomes. A hormone-receptor-positive breast cancer and a triple-negative breast cancer of the same size behave like fundamentally different diseases.
This shift has implications for the metastasis-stage relationship. As staging systems incorporate more biology, the gap between what “stage IV” means on paper and what it means for a specific patient continues to widen. Two people with stage IV breast cancer may be facing very different diseases, and reducing the conversation to the stage number alone misses what matters most.
The Gap Between Clinical and Pathological Staging
There is another layer of complexity that many patients are unaware of: the stage assigned before surgery (clinical staging) frequently does not match the stage assigned after surgery and microscopic examination (pathological staging). In head and neck cancers, discrepancies in lymph node staging have been found in roughly 38% of cases, with upstaging more common than downstaging.10PubMed Central. Comparison of Clinical and Pathological Staging in Patients with Head and Neck Cancer After Neck Dissection A separate study of oral cavity cancers found that clinical staging had about 82.5% overall accuracy in predicting the pathological tumor status, and the tumor extent was underestimated in roughly 10-14% of cases, often because of occult metastases in lymph nodes that were not detected by imaging.11PubMed. Discrepancy between cTNM and pTNM staging of oral cavity cancers and its prognostic significance
This means a patient initially told they do not have metastatic disease (and therefore are not stage IV) might turn out to have occult spread that changes their staging after tissue is examined under a microscope. The reverse also occurs, though less commonly. Staging is not a single fixed pronouncement; it can shift as more information becomes available.
What Happens When Cancer Recurs
A related question that many patients face is what happens to staging when a cancer that was previously treated comes back in a distant organ. If someone was treated for stage II breast cancer five years ago and now has cancer in their bones, is that stage IV? In practice, it is generally treated as metastatic (stage IV) disease. However, standard staging systems were not originally designed with recurrence in mind, and the terminology for classifying recurrent and metastatic disease after primary therapy remains inconsistent. Accurate assessment of disease extent is critical for selecting appropriate treatment when cancer recurs, yet standard staging systems often do not adequately address the classification and restaging terminology for this scenario.12PubMed Central. Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging Some institutions and clinical trials use prefix designations like “r” for recurrence or “y” for post-treatment to distinguish these situations from a cancer that was stage IV from the time of first diagnosis, but there is no single universally adopted standard.
New Technology Detecting Invisible Spread
Liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) testing, are adding yet another wrinkle. These blood-based tests can detect trace amounts of tumor DNA circulating in the bloodstream even when no metastasis is visible on scans. In gastric cancer patients, ctDNA was detected a median of about six months before imaging showed recurrence, and every patient who had detectable ctDNA at a time when scans were ambiguous ultimately went on to recur.13Cell Death & Disease. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer
This raises a question the staging system was not built to answer: if molecular evidence shows cancer cells are circulating or persisting somewhere in the body after apparently successful surgery, but no visible metastasis exists on imaging, is that metastatic disease? Currently, the answer is no in terms of formal staging. Staging still relies on imaging and, when available, tissue confirmation. But as liquid biopsy becomes more widely used, the gap between what the staging system says and what the biology shows will grow. A patient might be “stage II, no evidence of metastatic disease” by imaging criteria, yet have detectable residual cancer in their blood. How the staging system adapts to this new information is still being worked out.
Treatment Advances Changing What Stage IV Means
Even when metastatic cancer does fall cleanly into the stage IV category, what that stage means for a patient’s life has changed dramatically in the past decade. In non-small cell lung cancer, a population-level analysis identified two major turning points in survival trends over 15 years: one around 2010, associated with the adoption of targeted therapies, and another around 2014, tied to the introduction of immunotherapy.14PubMed Central. Immunotherapy Improves the Survival of Stage 4 Non–Small Cell Lung Cancer Patients at the US Population Level: The Real‐World Evidence In metastatic kidney cancer, first-line immunotherapy and combinations of targeted therapy with immunotherapy were associated with meaningfully improved survival compared with targeted therapy alone.15JAMA Network Open. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
These gains mean that a stage IV diagnosis in 2025 carries a different set of possibilities than it did in 2005. For some cancer types and molecular subtypes, metastatic disease has become a chronic condition that patients live with for years. For others, it remains rapidly fatal. The stage number communicates the anatomic extent of the disease but says almost nothing about the trajectory ahead without knowing the specific cancer type, its molecular features, and the treatment options available.
How Doctors Talk About Prognosis
One reason the “metastatic equals stage 4 equals terminal” equation persists in public understanding is that prognostic conversations between oncologists and patients tend to be vague. Research examining recorded interactions between oncologists and patients with advanced cancer found that while prognosis was discussed in the majority of these conversations, the descriptions were often imprecise and rarely included survival estimates. Oncologists frequently relied on ambiguous language, euphemisms, and jargon, and emphasized uncertainty before quickly shifting the conversation to treatment details.16PubMed Central. Discussing prognosis and treatment goals with patients with advanced cancer: A qualitative analysis of oncologists’ language When a patient hears they have “stage 4” and receives only vague reassurances about treatment options, they are left to fill the gaps with what they have absorbed from popular culture, where “stage 4” almost always means the end. The reality is messier, more variable, and in some cases substantially more hopeful than that narrative.
Cervical Cancer and FIGO Staging
Some cancer types use staging systems from specialty organizations rather than the AJCC’s TNM framework, and these systems define stage IV in their own terms. Cervical cancer, for example, uses the FIGO staging system maintained by the International Federation of Gynecology and Obstetrics. Under the revised 2018 FIGO system, stage IVB is defined by distant metastasis, including spread to organs like the lungs, liver, or bone, as well as distant lymph nodes.17International Journal of Gynecological Cancer. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain Stage IVA, by contrast, describes cancer that has invaded the bladder or rectum without distant spread. So in FIGO staging, as with prostate cancer in the AJCC system, a patient can have stage IV disease without any distant metastasis.
These parallel staging systems sometimes create confusion when patients see information about “stage IV” that does not match what their own oncologist has explained, particularly when the staging system uses a different framework or defines the boundary between stage III and stage IV differently than the one most people are familiar with from common solid tumors.